Published in Mod Pathol on August 07, 2015
Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. Mod Pathol (2015) 0.92
Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma. Oncotarget (2016) 0.76
New developments in the pathology of malignant lymphoma: a review of the literature published from May 2015-September 2015. J Hematop (2015) 0.76
Diagnostic and predictive biomarkers for lymphoma diagnosis and treatment in the era of precision medicine. Mod Pathol (2016) 0.75
Clinical impact of serum survivin positivity and tissue expression of EBV-encoded RNA in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. Oncotarget (2017) 0.75
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature (2000) 64.32
Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res (2003) 52.74
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med (2002) 19.60
A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med (1993) 17.71
A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med (1997) 12.65
Cancer cell metabolism: Warburg and beyond. Cell (2008) 11.80
Control of apoptosis and mitotic spindle checkpoint by survivin. Nature (1998) 8.60
CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol (2006) 8.53
Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med (1993) 6.77
Molecular diagnosis of Burkitt's lymphoma. N Engl J Med (2006) 6.10
Validating survivin as a cancer therapeutic target. Nat Rev Cancer (2003) 5.73
Chromosomal passengers and the (aurora) ABCs of mitosis. Trends Cell Biol (2001) 5.09
Survivin and the inner centromere protein INCENP show similar cell-cycle localization and gene knockout phenotype. Curr Biol (2000) 4.27
Structure of a Survivin-Borealin-INCENP core complex reveals how chromosomal passengers travel together. Cell (2007) 3.98
Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res (1998) 3.63
Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. Proc Natl Acad Sci U S A (2000) 3.44
Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res (2000) 3.24
Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene (2002) 3.12
MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood (2009) 3.10
Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin Cancer Res (2006) 3.00
Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. Blood (2002) 2.90
CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol (2011) 2.87
Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis. J Clin Invest (2004) 2.59
HBXIP functions as a cofactor of survivin in apoptosis suppression. EMBO J (2003) 2.47
A novel anti-apoptosis gene: Re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. J Clin Oncol (1999) 2.32
Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood (2000) 2.23
The case for survivin as a regulator of microtubule dynamics and cell-death decisions. Curr Opin Cell Biol (2006) 2.19
Inhibitor of apoptosis proteins: translating basic knowledge into clinical practice. Cancer Res (2004) 2.19
Anti-apoptosis gene, survivin, and prognosis of neuroblastoma. Lancet (1998) 2.08
Nuclear and cytoplasmic survivin: molecular mechanism, prognostic, and therapeutic potential. Cancer Res (2007) 1.87
Regulation of survivin function by Hsp90. Proc Natl Acad Sci U S A (2003) 1.86
Relapsed/refractory diffuse large B-cell lymphoma. Hematology Am Soc Hematol Educ Program (2011) 1.80
Solution structure of human survivin and its binding interface with Smac/Diablo. Biochemistry (2005) 1.60
Tumor content of the antiapoptosis molecule survivin and recurrence of bladder cancer. N Engl J Med (1999) 1.58
Expression and prognostic significance of survivin in de novo acute myeloid leukaemia. Br J Haematol (2000) 1.56
The Warburg effect: insights from the past decade. Pharmacol Ther (2012) 1.53
Nuclear or cytoplasmic expression of survivin: what is the significance? Int J Cancer (2005) 1.52
Advanced diffuse histiocytic lymphoma, a potentially curable disease. Lancet (1975) 1.49
miR-34a, miR-29c and miR-17-5p are downregulated in CLL patients with TP53 abnormalities. Leukemia (2009) 1.47
Broad spectrum and potent antitumor activities of YM155, a novel small-molecule survivin suppressant, in a wide variety of human cancer cell lines and xenograft models. Cancer Sci (2011) 1.43
Antitumor effects of YM155, a novel survivin suppressant, against human aggressive non-Hodgkin lymphoma. Leuk Res (2011) 1.40
Prognostic impact of immunohistochemical biomarkers in diffuse large B-cell lymphoma in the rituximab era. Cancer Sci (2009) 1.22
Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models. PLoS One (2012) 1.22
Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. Mod Pathol (2013) 1.21
Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study. Haematologica (2012) 1.21
Phase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer. J Transl Med (2004) 1.17
Acetylation directs survivin nuclear localization to repress STAT3 oncogenic activity. J Biol Chem (2010) 1.16
A phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B-cell lymphoma. Cancer (2011) 1.14
Prognostic factors for diffuse large B-cell lymphoma in the R(X)CHOP era. Ann Oncol (2014) 1.12
A potent immunogenic general cancer vaccine that targets survivin, an inhibitor of apoptosis proteins. Clin Cancer Res (2005) 1.10
Immunotherapeutic benefit of α-interferon (IFNα) in survivin2B-derived peptide vaccination for advanced pancreatic cancer patients. Cancer Sci (2012) 1.02
Immunogenic enhancement and clinical effect by type-I interferon of anti-apoptotic protein, survivin-derived peptide vaccine, in advanced colorectal cancer patients. Cancer Sci (2011) 0.99
Combination of YM155, a survivin suppressant, with bendamustine and rituximab: a new combination therapy to treat relapsed/refractory diffuse large B-cell lymphoma. Clin Cancer Res (2014) 0.99
Clinical and immunological evaluation of anti-apoptosis protein, survivin-derived peptide vaccine in phase I clinical study for patients with advanced or recurrent breast cancer. J Transl Med (2008) 0.98
Human inhibitor of apoptosis protein (IAP) survivin participates in regulation of chromosome segregation and mitotic exit. FASEB J (2001) 0.98
Molecular identification of mammalian phosphopentomutase and glucose-1,6-bisphosphate synthase, two members of the alpha-D-phosphohexomutase family. J Biol Chem (2007) 0.98
Prognostic factors in patients with diffuse large B cell lymphoma: Before and after the introduction of rituximab. Leuk Lymphoma (2008) 0.98
Antitumor cytotoxic T-cell response induced by a survivin peptide mimic. Cancer Immunol Immunother (2010) 0.90
Phase I clinical trial of survivin-derived peptide vaccine therapy for patients with advanced or recurrent oral cancer. Cancer Sci (2010) 0.90
Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma--is it necessary? Oncotarget (2015) 0.89
Genetic lesions in diffuse large B-cell lymphomas. Ann Oncol (2015) 0.89
Disturbed expression of the anti-apoptosis gene, survivin, and EPR-1 in hematological malignancies. Leuk Res (2000) 0.88
Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma. Oncotarget (2015) 0.88
Clinical implications of phosphorylated STAT3 expression in De Novo diffuse large B-cell lymphoma. Clin Cancer Res (2014) 0.88
Diffuse large B-cell lymphoma classification system that associates normal B-cell subset phenotypes with prognosis. J Clin Oncol (2015) 0.87
Prognostic impact of c-Rel nuclear expression and REL amplification and crosstalk between c-Rel and the p53 pathway in diffuse large B-cell lymphoma. Oncotarget (2015) 0.84
Prognostic significance of survivin and caspase-3 immunohistochemical expression in patients with diffuse large B-cell lymphoma treated with rituximab and CHOP. Pathol Oncol Res (2010) 0.83
Survivin expression in patients with newly diagnosed nodal diffuse large B cell lymphoma (DLBCL). Med Oncol (2012) 0.82
Genetic variation in Transaldolase 1 and risk of squamous cell carcinoma of the head and neck. Cancer Detect Prev (2008) 0.81
Challenges in the development of a survivin vaccine (SurVaxM) for malignant glioma. Expert Rev Vaccines (2014) 0.81
High Ki67 index and bulky disease remain significant adverse prognostic factors in patients with diffuse large B cell lymphoma before and after the introduction of rituximab. Acta Haematol (2011) 0.81
Comparison of prognostic models for patients with diffuse large B-cell lymphoma in the rituximab era. Ann Hematol (2013) 0.79
A new subtype-specific monoclonal antibody for IAP-survivin identifies high-risk patients with diffuse large B-cell lymphoma and improves the prognostic value of bcl-2. Int J Oncol (2008) 0.78
Combination of YM155, a survivin suppressant with a STAT3 inhibitor: a new strategy to treat diffuse large B-cell lymphoma. Leuk Res (2013) 0.78
Ovarian cancer vaccine candidate DPX-Survivac: positive interim results from phase 1. Hum Vaccin Immunother (2012) 0.77
Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial. Lancet Oncol (2015) 1.45
Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. Mod Pathol (2013) 1.21
Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases. Leuk Res (2014) 0.93
Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. Mod Pathol (2015) 0.92
Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma--is it necessary? Oncotarget (2015) 0.89
Immune checkpoint blockade: Releasing the brake towards hematological malignancies. Blood Rev (2015) 0.89
Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma. Oncotarget (2015) 0.88
Clinical implications of phosphorylated STAT3 expression in De Novo diffuse large B-cell lymphoma. Clin Cancer Res (2014) 0.88
Signaling pathway and dysregulation of PD1 and its ligands in lymphoid malignancies. Biochim Biophys Acta (2015) 0.86
Prognostic impact of c-Rel nuclear expression and REL amplification and crosstalk between c-Rel and the p53 pathway in diffuse large B-cell lymphoma. Oncotarget (2015) 0.84
Bone marrow fibrosis in patients with primary myelodysplastic syndromes has prognostic value using current therapies and new risk stratification systems. Mod Pathol (2013) 0.83
B acute lymphoblastic leukemia with t(14;19)(q32;p13.1) involving IGH/EPOR: a clinically aggressive subset of disease. Mod Pathol (2013) 0.83
Plasma circulating-microRNA profiles are useful for assessing prognosis in patients with cytogenetically normal myelodysplastic syndromes. Mod Pathol (2014) 0.82
Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries. Oncotarget (2015) 0.82